Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability